Platform
Solutions
Resources
Company
REQUEST A DEMO

More results...

More results...

Platform
- THE SOPHiA DDM™ PLATFORM
- .
  - Alamut™ Visual Plus
  - OncoPortal™ Plus
Solutions
Resources
Company
- ABOUT SOPHiA GENETICS
- USEFUL LINKS
REQUEST A DEMO
SIGN IN

SOPHiA DDM Dx mode User manual_IT

by [email protected] | Jun 1, 2022

File Type: pdf

File Size: 10 MB

Categories: Instructions for Use, IVD

Tags: Italian

Search for:

Recent Posts

SOPHiA GENETICS Announces It Joins the European Liquid Biopsy Society at ECP 2024
SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024
SOPHiA GENETICS Unveils New Generation of the SOPHiA DDM™ Platform at Morgan Stanley Healthcare Conference 2024
SOPHiA DDM™ Platform Certified Under IVDR
Enhancing variant interpretation: Obtaining answers from a vast universe of data

Recent Comments

Platform

The SOPHiA DDM™ Platform
Genomics
Multimodal
Alamut™ Visual Plus
OncoPortal™ Plus
SOPHiA GENETICS Integrated Solutions

SOLUTIONS

Oncology
Rare and Inherited Diseases
BioPharma

RESOURCES

Publications
Case Studies
Webinars
Science Hub
FAQ
Technical Documents
Quality Certification

Company

About Us
Leadership Team
Investors
Press Releases
Press Kit
Blog

Company

Events
Careers
Partner With Us
Contact Us
Request A Demo

© 2021-2024 SOPHiA GENETICS. All rights reserved.

Privacy Policy | Cookie Policy | Terms of Use | Sitemap |
Index égalité HF en France | Axes du plan d’actions égalité H_F 2023_2024

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in Europe and Turkey. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in Europe, Turkey and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

Somatic gene variant annotations and related content have been powered by, without limitation, The Jackson Laboratory Clinical Knowledgebase (JAX-CKB™).

SOPHiA GENETICS

Platform

The SOPHiA DDM™ Platform
Genomics
Multimodal
Alamut™ Visual Plus
OncoPortal™ Plus
SOPHiA GENETICS Integrated Solutions

SOLUTIONS

Oncology
Rare and Inherited Diseases
BioPharma

RESOURCES

Publications
Case Studies
Webinars
Science Hub
FAQ
Technical Documents
Quality Certification

Company

About Us
Leadership Team
Investors
Press Releases
Press Kit
Blog
Quality Certification
Events
Careers
Partner With Us
Contact Us
Request A Demo

© 2021 SOPHiA GENETICS. All rights reserved.

Privacy Policy | Cookie Policy | Terms of Use | Sitemap |
Index égalité HF en France | Axes du plan d’actions égalité H_F 2023_2024

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in Europe and Turkey. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in Europe, Turkey and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

Somatic gene variant annotations and related content have been powered by, without limitation, The Jackson Laboratory Clinical Knowledgebase (JAX-CKB™).

';